Literature DB >> 20214605

Designing phage therapeutics.

Lawrence D Goodridge1.   

Abstract

Phage therapy is the application of phages to bodies, substances, or environments to effect the biocontrol of pathogenic or nuisance bacteria. To be effective, phages, minimally, must be capable of attaching to bacteria (adsorption), killing those bacteria (usually associated with phage infection), and otherwise surviving (resisting decay) until they achieve attachment and subsequent killing. While a strength of phage therapy is that phages that possess appropriate properties can be chosen from a large diversity of naturally occurring phages, a more rational approach to phage therapy also can include post-isolation manipulation of phages genetically, phenotypically, or in terms of combining different products into a single formulation. Genetic manipulation, especially in these modern times, can involve genetic engineering, though a more traditional approach involves the selection of spontaneously occurring phage mutants during serial transfer protocols. While genetic modification typically is done to give rise to phenotypic changes in phages, phage phenotype alone can also be modified in vitro, prior to phage application for therapeutic purposes, as for the sake of improving phage lethality (such as by linking phage virions to antibacterial chemicals such as chloramphenicol) or survival capabilities (e.g., via virion PEGylation). Finally, phages, both naturally occurring isolates or otherwise modified constructs, can be combined into cocktails which provide collectively enhanced capabilities such as expanded overall host range. Generally these strategies represent different routes towards improving phage therapy formulations and thereby efficacy through informed design.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20214605     DOI: 10.2174/138920110790725348

Source DB:  PubMed          Journal:  Curr Pharm Biotechnol        ISSN: 1389-2010            Impact factor:   2.837


  35 in total

Review 1.  Biofilm control with natural and genetically-modified phages.

Authors:  Amir Mohaghegh Motlagh; Ananda Shankar Bhattacharjee; Ramesh Goel
Journal:  World J Microbiol Biotechnol       Date:  2016-03-01       Impact factor: 3.312

2.  Application of filamentous phages in environment: A tectonic shift in the science and practice of ecorestoration.

Authors:  Radhey Shyam Sharma; Swagata Karmakar; Pankaj Kumar; Vandana Mishra
Journal:  Ecol Evol       Date:  2019-01-25       Impact factor: 2.912

Review 3.  Pharmacologically Aware Phage Therapy: Pharmacodynamic and Pharmacokinetic Obstacles to Phage Antibacterial Action in Animal and Human Bodies.

Authors:  Krystyna Dąbrowska; Stephen T Abedon
Journal:  Microbiol Mol Biol Rev       Date:  2019-10-30       Impact factor: 11.056

Review 4.  Managing urinary tract infections through phage therapy: a novel approach.

Authors:  Shikha Malik; Parveen Kaur Sidhu; J S Rana; Kiran Nehra
Journal:  Folia Microbiol (Praha)       Date:  2019-09-07       Impact factor: 2.099

5.  Lytic myophage Abp53 encodes several proteins similar to those encoded by host Acinetobacter baumannii and phage phiKO2.

Authors:  Chia-Ni Lee; Tsai-Tien Tseng; Juey-Wen Lin; Yung-Chieh Fu; Shu-Fen Weng; Yi-Hsiung Tseng
Journal:  Appl Environ Microbiol       Date:  2011-08-05       Impact factor: 4.792

Review 6.  Biological challenges of phage therapy and proposed solutions: a literature review.

Authors:  Katherine M Caflisch; Gina A Suh; Robin Patel
Journal:  Expert Rev Anti Infect Ther       Date:  2019-12-02       Impact factor: 5.091

7.  Phage treatment of human infections.

Authors:  Stephen T Abedon; Sarah J Kuhl; Bob G Blasdel; Elizabeth Martin Kutter
Journal:  Bacteriophage       Date:  2011-03

8.  Pros and cons of phage therapy.

Authors:  Catherine Loc-Carrillo; Stephen T Abedon
Journal:  Bacteriophage       Date:  2011-03

9.  Characterization and comparative genomic analysis of a novel bacteriophage, SFP10, simultaneously inhibiting both Salmonella enterica and Escherichia coli O157:H7.

Authors:  Minjung Park; Ju-Hoon Lee; Hakdong Shin; Minsik Kim; Jeongjoon Choi; Dong-Hyun Kang; Sunggi Heu; Sangryeol Ryu
Journal:  Appl Environ Microbiol       Date:  2011-10-21       Impact factor: 4.792

10.  wksl3, a New biocontrol agent for Salmonella enterica serovars enteritidis and typhimurium in foods: characterization, application, sequence analysis, and oral acute toxicity study.

Authors:  Hyun-Wol Kang; Jae-Won Kim; Tae-Sung Jung; Gun-Jo Woo
Journal:  Appl Environ Microbiol       Date:  2013-01-18       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.